World Journal of Surgery

, Volume 43, Issue 12, pp 3110–3119 | Cite as

Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases

  • Francesca RattiEmail author
  • David Fuks
  • Federica Cipriani
  • Brice Gayet
  • Luca Aldrighetti
Original Scientific Report



The aim of this study was to compare patients undergoing combined colorectal and hepatic surgery with and without neoadjuvant chemotherapy to clarify the prognostic advantage of preoperative oncological treatment in a case-matched analysis using propensity scores and to identify factors predictive of good prognosis in a selected population of Synchronous ColoRectal Liver Metastases (SCRLM).


A total of 73 patients who underwent upfront elective combined surgery without preoperative CT for SCRLM in two European tertiary referral centers were selected and constituted the study group (NoNACT group). The NoNACT group was matched (ratio 1:1) with patients who were operated after chemotherapy with neoadjuvant intent (NACT group, the control group). The matching was achieved based on six covariates representative of patients and disease characteristics.


While the characteristics of both colorectal and hepatic procedures were similar, the NoNACT group, as compared to the NACT group, had lower blood loss (200 mL vs. 550 mL). Postoperative stay (9 vs. 12 days) and morbidity rate (24.7% vs. 32.9%) were reduced in the NoNACT compared with the NACT group. Mid- and long-term outcomes were comparable. At multivariable analysis, predictors of long-term outcome were: right colonic neoplasms, RAS mutational status, CRS score ≥3 and the absence of perioperative chemotherapy.


Preoperative neoadjuvant chemotherapy in patients with colorectal cancer and synchronous resectable liver metastases does not influence the risk of recurrence in patients with favorable tumor biology, while it was associated with increased intraoperative blood loss and morbidity. There is no strong evidence to recommend upfront chemotherapy in the absence of negative prognostic factors.


Compliance with ethical standards

Conflict of interest

The authors of this manuscript have no conflicts of interest to disclose and further disclose any commercial interest that they may have in the subject of study and the source of any financial or material support.


  1. 1.
    Lykoudis PM, O'Reilly D, Nastos K, Fusai G et al (2014) Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 101(6):605–612CrossRefGoogle Scholar
  2. 2.
    Kelly ME, Spolverato G, Lê GN et al (2015) (2014) Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol 111(3):341–351CrossRefGoogle Scholar
  3. 3.
    Hallet J, Sa Cunha A, Adam R et al (2016) Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg 103(10):1366–1376CrossRefGoogle Scholar
  4. 4.
    Smith JJ, D'Angelica MI (2015) Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin N Am 29(1):61–84CrossRefGoogle Scholar
  5. 5.
    Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318 (discussion 318–321)CrossRefGoogle Scholar
  6. 6.
    Petrelli NJ (2006) Systemic chemotherapy should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient. Ann Surg Oncol 13(2):137–139CrossRefGoogle Scholar
  7. 7.
    Viganò L, Langella S, Ferrero A et al (2013) Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Ann Surg Oncol 20(3):938–945CrossRefGoogle Scholar
  8. 8.
    Adam R, De Gramont A, Figueras J et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17(10):1225–1239CrossRefGoogle Scholar
  9. 9.
    Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016CrossRefGoogle Scholar
  10. 10.
    Bonney GK, Coldham C, Adam R et al (2015) Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; an international multi-center data analysis using LiverMetSurvey. J Surg Oncol 111(6):716–724CrossRefGoogle Scholar
  11. 11.
    Ratti F, Catena M, Di Palo S et al (2016) Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score-based analysis. Surg Endosc 30(11):4934–4945CrossRefGoogle Scholar
  12. 12.
    Ratti F, Catena M, Di Palo S et al (2015) Laparoscopic approach for primary colorectal cancer improves outcome of patients undergoing combined open hepatic resection for liver metastases. World J Surg 39(10):2573–2582. CrossRefPubMedGoogle Scholar
  13. 13.
    Gavriilidis P, Sutcliffe RP, Hodson J et al (2018) Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis. HPB (Oxford) 20(1):11–19CrossRefGoogle Scholar
  14. 14.
    Slesser AA, Simillis C, Goldin R et al (2013) A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. Surg Oncol 22(1):36–47CrossRefGoogle Scholar
  15. 15.
    Yin Z, Liu C, Chen Y et al (2013) Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed? Hepatology 57(6):2346–2357CrossRefGoogle Scholar
  16. 16.
    Umehara M, Umehara Y, Takahashi K et al (2016) Preoperative chemotherapy with bevacizumab extends disease-free survival after resection of liver metastases from colorectal cancer. Anticancer Res 36(4):1949–1954PubMedGoogle Scholar
  17. 17.
    Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendation from an expert panel. Ann Oncol 20(6):985–992CrossRefGoogle Scholar
  18. 18.
    Ratti F, Fiorentini G, Cipriani F et al (2018) Laparoscopic vs open surgery for colorectal liver metastases. JAMA Surg. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Aldrighetti L, Ratti F, Cillo U et al (2017) Diffusion, outcomes and implementation of minimally invasive liver surgery: a snapshot from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Updates Surg 69(3):271–283CrossRefGoogle Scholar
  20. 20.
    Tabchouri N, Gayet B, Okumura S et al (2018) Recurrence patterns after laparoscopic resection of colorectal liver metastases. Surg Endosc. CrossRefPubMedGoogle Scholar
  21. 21.
    Nomi T, Fuks D, Louvet C et al (2016) Outcomes of laparoscopic liver resection for patients with large colorectal liver metastases: a case-matched analysis. World J Surg 40(7):1702–1708. CrossRefPubMedGoogle Scholar
  22. 22.
    Fretland ÅA, Dagenborg VJ, Bjørnelv GMW et al (2018) (2018) Laparoscopic versus open resection for colorectal liver metastases: the OSLO-COMET randomized controlled trial. Ann Surg 267(2):199–207CrossRefGoogle Scholar
  23. 23.
    Abu Hilal M, Aldrighetti L, Dagher I et al (2018) The Southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation. Ann Surg 268(1):11–18CrossRefGoogle Scholar
  24. 24.
    Tohme S, Goswami J, Han K et al (2015) Minimally invasive resection of colorectal cancer liver metastases leads to an earlier initiation of chemotherapy compared to open surgery. J Gastrointest Surg 19(12):2199–2206CrossRefGoogle Scholar
  25. 25.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefGoogle Scholar
  26. 26.
    Robinson SM, Wilson CH, Burt AD et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19(13)4287–4299CrossRefGoogle Scholar
  27. 27.
    Ratti F, Cipriani F, Catena M et al (2014) Liver failure in patients treated with chemotherapy for colorectal liver metastases: role of chronic disease scores in patients undergoing major liver surgery. A case-matched analysis. Eur J Surg Oncol 40(11)1550–1556CrossRefGoogle Scholar
  28. 28.
    Zhao J, van Mierlo KMC, Gómez-Ramírez J et al (2017) Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 104(8):990–1002CrossRefGoogle Scholar
  29. 29.
    Ratti F, Cipriani F, Reineke R et al (2018) The clinical and biological impacts of the implementation of fast-track perioperative programs in complex liver resections: a propensity score-based analysis between the open and laparoscopic approaches. Surgery 164(3):395–403CrossRefGoogle Scholar
  30. 30.
    Serenari M, Alvarez FA, Ardiles V et al (2018) (2018) The ALPPS approach for colorectal liver metastases: impact of KRAS mutation status in survival. Dig Surg 35(4):303–310CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • Francesca Ratti
    • 1
    Email author
  • David Fuks
    • 2
  • Federica Cipriani
    • 1
  • Brice Gayet
    • 2
  • Luca Aldrighetti
    • 1
  1. 1.Hepatobiliary Surgery DivisionIRCCS San Raffaele HospitalMilanItaly
  2. 2.Department of Digestive DiseaseInstitut Mutualiste MontsourisParisFrance

Personalised recommendations